Supernus Pharmaceuticals (NASDAQ:SUPN) Upgraded by StockNews.com to “Strong-Buy” Rating

Supernus Pharmaceuticals (NASDAQ:SUPN) was upgraded by stock analysts at StockNews.com from a “buy” rating to a “strong-buy” rating in a research report issued to clients and investors on Tuesday.

Separately, Cantor Fitzgerald reaffirmed a “neutral” rating and issued a $36.00 price target on shares of Supernus Pharmaceuticals in a research report on Wednesday, February 26th.

Supernus Pharmaceuticals Price Performance

Shares of NASDAQ SUPN traded down $1.07 during mid-day trading on Tuesday, hitting $31.68. The company had a trading volume of 608,392 shares, compared to its average volume of 479,334. The company has a market capitalization of $1.77 billion, a PE ratio of 29.61 and a beta of 0.83. The business’s 50-day simple moving average is $34.91 and its 200 day simple moving average is $35.06. Supernus Pharmaceuticals has a 1-year low of $25.53 and a 1-year high of $40.28.

Insider Transactions at Supernus Pharmaceuticals

In other Supernus Pharmaceuticals news, VP Padmanabh P. Bhatt sold 9,477 shares of Supernus Pharmaceuticals stock in a transaction dated Tuesday, February 4th. The stock was sold at an average price of $39.70, for a total transaction of $376,236.90. Following the completion of the sale, the vice president now directly owns 10,149 shares of the company’s stock, valued at $402,915.30. The trade was a 48.29 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, SVP Jonathan Rubin sold 927 shares of the stock in a transaction dated Friday, February 21st. The shares were sold at an average price of $39.15, for a total value of $36,292.05. Following the completion of the transaction, the senior vice president now owns 7,853 shares in the company, valued at approximately $307,444.95. The trade was a 10.56 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders sold 11,104 shares of company stock valued at $440,263. Insiders own 9.30% of the company’s stock.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the stock. Vident Advisory LLC lifted its position in Supernus Pharmaceuticals by 2.2% in the fourth quarter. Vident Advisory LLC now owns 14,392 shares of the specialty pharmaceutical company’s stock valued at $520,000 after acquiring an additional 309 shares during the last quarter. Summit Investment Advisors Inc. lifted its holdings in shares of Supernus Pharmaceuticals by 7.6% in the 4th quarter. Summit Investment Advisors Inc. now owns 5,253 shares of the specialty pharmaceutical company’s stock valued at $190,000 after purchasing an additional 369 shares during the last quarter. Bank of Montreal Can boosted its position in shares of Supernus Pharmaceuticals by 6.6% in the 4th quarter. Bank of Montreal Can now owns 7,595 shares of the specialty pharmaceutical company’s stock valued at $275,000 after purchasing an additional 473 shares during the period. Exchange Traded Concepts LLC grew its stake in Supernus Pharmaceuticals by 2.6% during the 4th quarter. Exchange Traded Concepts LLC now owns 22,119 shares of the specialty pharmaceutical company’s stock worth $800,000 after buying an additional 560 shares during the last quarter. Finally, HighTower Advisors LLC increased its position in Supernus Pharmaceuticals by 7.3% during the fourth quarter. HighTower Advisors LLC now owns 9,130 shares of the specialty pharmaceutical company’s stock worth $330,000 after buying an additional 624 shares during the period.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.